A landmark international study published in the New England Journal of Medicine has challenged four decades of standard heart attack treatment, finding that beta blockers provide no meaningful benefit for patients with uncomplicated heart attacks and normal heart function. The research, involving over 5,000 patients across multiple countries, suggests that millions of patients worldwide may be receiving unnecessary medication that could potentially cause harm, particularly among women.
Beta Blocker Outcomes by Patient Group
Risk of death, heart attack, or hospitalization at 3.5 years, percentage
Source: New England Journal of Medicine, 2026 | Georgian Medical Journal News
Decades of Treatment Practice Questioned
Beta blockers have been a cornerstone of post-heart attack care since the 1980s, when early studies demonstrated their life-saving potential. However, according to Dr. Sanne Jorstad, lead investigator from Amsterdam University Medical Centers, modern heart attack treatment has evolved dramatically, potentially negating the historical benefits of these medications.
The study, conducted between 2010 and 2022, followed patients who had suffered ST-elevation myocardial infarctions (STEMI) – the most severe type of heart attack – but whose heart function remained normal after treatment. All participants received current standard care including FDA-approved blood thinners, cholesterol-lowering medications, and emergency coronary interventions.
Concerning Gender Differences Emerge
Perhaps the most striking finding concerned women’s responses to beta blocker therapy. According to the study data, women taking beta blockers experienced a 9.5% rate of major adverse cardiac events over 3.5 years, compared to just 6.5% among women who didn’t receive the medication – a statistically significant difference that has prompted calls for immediate clinical guideline reviews.
“The differential response between men and women was unexpected and clinically significant,” noted Dr. Jorstad in the study publication. This gender-based difference adds to mounting evidence that cardiovascular medications may affect men and women differently, yet most historical trials predominantly enrolled male participants.
Modern Heart Attack Care Changes the Equation
The study’s findings reflect how dramatically heart attack treatment has improved since beta blockers first proved beneficial in the 1980s. Modern patients receive rapid reperfusion therapy, advanced stent technology, and optimized medical therapy that was unavailable during earlier eras when beta blockers first demonstrated benefit.
Dr. Gregg Fonarow, a cardiologist at UCLA who was not involved in the study, told the American Heart Association that these results align with several smaller studies questioning beta blocker necessity in the modern era. The convergence of evidence suggests that treatment guidelines established decades ago may need substantial revision.
Global Treatment Implications
The study’s international scope – encompassing patients from Europe, North America, and Asia – strengthens its applicability to diverse populations worldwide. According to the World Health Organization, approximately 17.9 million people die from cardiovascular diseases annually, making heart attack treatment protocols a global health priority.
Healthcare systems now face the challenge of updating treatment protocols while ensuring patient safety during the transition. The study authors recommend that clinicians carefully evaluate the continued need for beta blockers in patients with preserved heart function, particularly women, while maintaining other proven therapies. This research reinforces the importance of evidence-based medicine adapting as treatment options evolve.
Women taking beta blockers after uncomplicated heart attacks experienced a 46% higher rate of major adverse cardiac events compared to women not receiving the medication over 3.5 years of follow-up
— Dr. Sanne Jorstad, Amsterdam University Medical Centers (New England Journal of Medicine, 2026)
Key takeaways
- Beta blockers showed no benefit for 5,020 heart attack patients with normal heart function in the largest trial of its kind
- Women taking beta blockers faced 46% higher risk of death, heart attack, or heart failure hospitalization compared to women without the medication
- Modern heart attack treatment including rapid stenting and optimized medical therapy may have negated historical benefits of beta blockers
- Cardiologists worldwide are now reconsidering four decades of standard post-heart attack treatment protocols
Frequently asked questions
Should I stop taking beta blockers after reading this study?
No, patients should never stop prescribed medications without consulting their cardiologist first. This study applies specifically to patients with uncomplicated heart attacks and normal heart function – beta blockers remain beneficial for many other cardiac conditions including heart failure and certain arrhythmias.
Why did beta blockers work in older studies but not this one?
Heart attack treatment has revolutionized since the 1980s when beta blockers first proved beneficial. Modern patients receive rapid emergency stenting, advanced blood thinners, and optimized medications that dramatically improve outcomes, potentially making additional beta blocker benefits negligible.
Are women at higher risk from all heart medications?
Not necessarily, but this study adds to evidence that cardiovascular medications may affect men and women differently. Historically, most cardiac trials enrolled predominantly male participants, potentially missing important gender-based differences in drug responses.
This landmark study represents a pivotal moment in cardiovascular medicine, demonstrating how evidence-based practice must evolve as treatment capabilities advance. As healthcare systems worldwide grapple with updating four decades of established protocols, the research underscores the critical importance of ongoing clinical trials that reflect modern treatment realities and diverse patient populations.
Source: Common heart drug taken by millions found useless — and possibly dangerous
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
